Jul 3 |
Insmed Presenting More Positive Data for Prospective Drug Treatment for Bronchiectasis This Week
|
Jul 3 |
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
|
Jul 2 |
Pharma companies shape competitive pipeline for bronchiectasis
|
Jun 27 |
Insmed redeems all $225 million of outstanding 1.75% convertible senior notes
|
Jun 27 |
Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025
|
Jun 14 |
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
|
Jun 11 |
Top 4 Health Care Stocks That May Keep You Up At Night This Month
|
Jun 5 |
Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
May 30 |
Insmed to Host Commercial Webinar on June 4, 2024
|
May 30 |
Insmed announces pricing of $650M public offering
|